TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21681081

Group type: EXPERIMENTAL
Intervention: N₂O group
Number of subjects: 2050

Group type: COMPARATOR
Intervention: N₂O-free group
Number of subjects: 2050
Study: 19915221

Group type: EXPERIMENTAL
Intervention: Cangrelor (intravenous, administered 30 minutes before PCI and continued for 2 hours after PCI)
Number of subjects: 8877

Group type: COMPARATOR
Intervention: Clopidogrel (600 mg oral loading dose, administered 30 minutes before PCI)
Number of subjects: 8877

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 8877

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 8877
Study: 17296187

Group type: EXPERIMENTAL
Intervention: Cinnamon extract
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15220230

Group type: EXPERIMENTAL
Intervention: Lifestyle case management (individual and group education, support, and referral by registered dietitians; cost: $350 per person)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Lifestyle case management
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (educational material)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study: 11576938

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Predialysis patients (CRF)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control patients (nonuremic)
Number of subjects: 23
Study: 9701531

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rabeprazole 30 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7974162

Group type: EXPERIMENTAL
Intervention: Intermittent electrostimulation with active muscle training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent electrostimulation without active muscle training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2553528

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (1500 aPTT once daily)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sodium heparin (5000 IU three times daily)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 300
Study: 17894044

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Number of subjects: 0
Study: 31104832

Group type: EXPERIMENTAL
Intervention: Two doses of fIPV (Group D)
Number of subjects: 1076

Group type: COMPARATOR
Intervention: fIPV booster (Group B)
Number of subjects: 1076
Study: 28899892

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (ICBT) for 15 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive behavioural group therapy (CBGT) for 15 weeks
Number of subjects: 126
Study: 26658938

Group type: EXPERIMENTAL
Intervention: Community Treatment Assistants (CTAs) with additional half-day training and a TT screening card
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care CTAs
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Novel screening tool
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care screening
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 23580379

Group type: EXPERIMENTAL
Intervention: Case management by healthcare assistants
Number of subjects: 562

Group type: COMPARATOR
Intervention: Control group (no case management)
Number of subjects: 562
Study: 21342005

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) and subepithelial connective tissue graft (SCTG) using a full-thickness flap reflection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) associated with a subepithelial connective tissue graft (SCTG) and partial-thickness flap reflection
Number of subjects: 20
Study: 17588276

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 15184958

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% + TDC
Number of subjects: 80
Study: 12535752

Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment in patients with subclinical hypothyroidism (SCH)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Overt hypothyroidism (OH)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Subclinical hypothyroidism (SCH)
Number of subjects: 124
Study: 10908004

Group type: EXPERIMENTAL
Intervention: Eight models of outpatient treatment for methamphetamine dependence (treatment-as-usual)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matrix model
Number of subjects: 0
Study: 9039444

Group type: EXPERIMENTAL
Intervention: Streptomycin-thiacetazone-isoniazid (STH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin-isoniazid-pyrazinamide (RHZ)
Number of subjects: 0
Study: 1538597

Group type: EXPERIMENTAL
Intervention: No-touch technique without any other preparation aids (Group I)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Distention at 70-120 mm Hg with balanced pH electrolyte solution (Group II)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Distention at 70-120 mm Hg with balanced pH electrolyte solution plus nitroglycerin (1 microgram/ml) (Group III)
Number of subjects: 29
Study: 6377994

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Breathing (IPPB) for 15 min 4 times daily
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS) 4 times daily
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercises (DBE) for 15 min 4 times daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no respiratory treatment)
Number of subjects: 172
Study: 31278814

Group type: EXPERIMENTAL
Intervention: Current smokers (n=33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Never-smokers (n=33)
Number of subjects: 66
Study: 29423540

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 810

Group type: COMPARATOR
Intervention: ACE inhibitors (ACEI)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Sartans
Number of subjects: 810
Study: 26526055

Group type: EXPERIMENTAL
Intervention: Test group (predictive model development)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Validation group (predictive model testing)
Number of subjects: 284
Study: 24901305

Group type: EXPERIMENTAL
Intervention: 75 g carbohydrate (sucrose) 45 min before exercise
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2 × 0.2 g · kg‐1 sodium bicarbonate (NaHCO3) 90 and 20 min before exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (H2O for carbohydrate group, 2 × 0.14 g · kg‐1 NaCl for sodium bicarbonate group)
Number of subjects: 17
Study: 22296950

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care program (e-health intervention and integrated care management)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care program
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 212
Study: 20214718

Group type: EXPERIMENTAL
Intervention: LC 40 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: LC 80 mg
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 18797094

Group type: EXPERIMENTAL
Intervention: Soft occlusal splint therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pharmacotherapy (muscle relaxants and analgesics)
Number of subjects: 40
Study: 29092729

Group type: EXPERIMENTAL
Intervention: Zaltoprofen capsule (80 mg) under fasting state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zaltoprofen tablet (80 mg) under fasting state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zaltoprofen capsule (80 mg) under fed state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zaltoprofen tablet (80 mg) under fed state
Number of subjects: 24
Study: 12845215

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study: 10702455

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg (Group T20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg (Group T40)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 4 mL (Group NS)
Number of subjects: 60
Study: 9316597

Group type: EXPERIMENTAL
Intervention: Early discharge with clinical nurse specialist transitional follow-up care (N = 44)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (N = 52)
Number of subjects: 96
Study: 8174947

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily) + Cisapride (20 mg twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily)
Number of subjects: 18
Study: 3985039

Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aerosol beclomethasone (16 puffs daily)
Number of subjects: 12
Study: 29705283

Group type: EXPERIMENTAL
Intervention: Temporary implantable nitinol device (TIND)
Number of subjects: 2
Study: 27136498

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sleep education control
Number of subjects: 134
Study: 24727024

Group type: EXPERIMENTAL
Intervention: High-competitive rivals at high fertility
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-competitive rivals at high fertility
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-competitive rivals at low fertility
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-competitive rivals at low fertility
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline testosterone levels
Number of subjects: 34
Study: 23135583

Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 94

Group type: COMPARATOR
Intervention: W-pouch
Number of subjects: 94
Study: 20928906

Group type: EXPERIMENTAL
Intervention: EAA without resistance training (AA, n = 7)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: EAA 3 h after resistance training (RT, n = 12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: EAA 5 min before resistance training (AART, n = 12)
Number of subjects: 31
Study: 18349328

Group type: EXPERIMENTAL
Intervention: Simulation associated with mental illness stigma
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simulation not associated with mental illness stigma
Number of subjects: 24
Study: 15620828

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intermittent dosing of piperacillin-tazobactam
Number of subjects: 24
Study: 12807810

Group type: EXPERIMENTAL
Intervention: Computer interpretation (CI) of EKGs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No computer interpretation (CI) of EKGs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correct computer interpretation (CI) included
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretation (CI) provided
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretation (CI) presented with EKG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretation (CI) not presented with EKG
Number of subjects: 0
Study: 10227009

Group type: EXPERIMENTAL
Intervention: 1.25 mg/day Tibolone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Tibolone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 8712192

Group type: EXPERIMENTAL
Intervention: Community-wide and individual health education intervention
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 2394
Study: 1905445

Group type: EXPERIMENTAL
Intervention: Mashed food (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal solid food (group B)
Number of subjects: 46
Study: 6374680

Group type: EXPERIMENTAL
Intervention: Piretanide (2 x 6 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (2 x 25 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (2 x 50 mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study: 30022544

Group type: EXPERIMENTAL
Intervention: BF-200 ALA gel (7.8% 5-aminolaevulinic acid)
Number of subjects: 52

Group type: COMPARATOR
Intervention: MAL cream (16% methyl-aminolaevulinate)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BF-200 ALA gel
Number of subjects: 52

Group type: COMPARATOR
Intervention: MAL cream
Number of subjects: 52
Study: 28731385

Group type: EXPERIMENTAL
Intervention: Kids SIP smartER
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 74
Study: 27086243

Group type: EXPERIMENTAL
Intervention: 1Hz rTMS
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10Hz rTMS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study: 25167977

Group type: COMPARATOR
Intervention: Whole milk (3.25% M.F.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simulated milk beverage (based on milk macronutrients)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Complete milk protein (16g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lactose (24g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Milk fat (16g)
Number of subjects: 12
Study: 21557778

Group type: EXPERIMENTAL
Intervention: Pre-filled pen
Number of subjects: 421

Group type: COMPARATOR
Intervention: Pre-filled syringe
Number of subjects: 421
Study: 21180005

Group type: EXPERIMENTAL
Intervention: Group 1: Silicacoating amalgam, etching dentin, silane application on amalgam, primer/bonding on dentin, opaquer on amalgam, resin composite on both
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 2: Etching dentin, silicacoating amalgam, silane application on amalgam, primer/bonding on dentin, opaquer on amalgam, resin composite on both
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 3: Etching dentin, primer/bonding on dentin, opaquer, resin composite
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group 4: Silicacoating, silane application, opaquer, resin composite
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group 5: Opaquer, resin composite
Number of subjects: 50
Study: 17428114

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2, 4, or 8 mg tablets once daily)
Number of subjects: 2595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2595
Study: 16919576

Group type: EXPERIMENTAL
Intervention: LBBB reference file
Number of subjects: 49

Group type: COMPARATOR
Intervention: General reference database
Number of subjects: 49
Study: 11860415

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg b.d.), Clarithromycin (500 mg b.d.), Amoxicillin (1 g b.d.)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.d.), Bismuth subsalicylate (600 mg q.d.s.), Metronidazole (400 mg t.d.s.), Tetracycline (500 mg q.d.s.)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance
Number of subjects: 84
Study: 10457580

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 61
Study: 7615102

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) - 1,000 micrograms intranasal buserelin acetate daily for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo - no active treatment for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Number of subjects: 30
Study: 2798990

Group type: EXPERIMENTAL
Intervention: Phenformin (50 mg bid)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pre-study
Number of subjects: 10
Study: 299896

Group type: EXPERIMENTAL
Intervention: Aspirin (4 gm/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (2.4 gm/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetaminophen (14 days prior to each period)
Number of subjects: 14
Study: 30592553

Group type: EXPERIMENTAL
Intervention: Paxerol (325 mg acetaminophen and 150 mg ibuprofen per tablet) at low dose (1 tablet), mid dose (2 tablets), and high dose (3 tablets) for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paxerol (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including Paxerol and placebo)
Number of subjects: 0
Study: 28941152

Group type: EXPERIMENTAL
Intervention: Immediate-loading protocol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional loading protocol
Number of subjects: 39
Study: 25495209

Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTO)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 333
Study: 23619906

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (250 mg magnesium oxide daily for 8 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 21899409

Group type: EXPERIMENTAL
Intervention: PTAS with the use of the Wingspan stent system
Number of subjects: 451

Group type: COMPARATOR
Intervention: Aggressive medical management alone
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 451
Study: 19255381

Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary diagnostic facility
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study: 16924991

Group type: EXPERIMENTAL
Intervention: Bleaching + 10% sodium ascorbate solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bleaching + 10% sodium ascorbate hydrogel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bleaching + 20% sodium ascorbate hydrogel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bleaching (10% carbamide peroxide gel)
Number of subjects: 60
Study: 15020394

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy by a research GP near their home address
Number of subjects: 151

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 151
Study: 16808802

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (25 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 10561343

Group type: EXPERIMENTAL
Intervention: Concurrent therapy (cisplatin 80 mg/m² on days 1 and 29, vindesine 3 mg/m² on days 1, 8, 29, and 36, mitomycin 8 mg/m² on days 1 and 29, RT starting on day 2 at 28 Gy)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 320

Group type: COMPARATOR
Intervention: Sequential therapy (same chemotherapy but RT initiated after completing CT at 56 Gy)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Sequential therapy
Number of subjects: 320
Study: 7495243

Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study: 1789063

Group type: EXPERIMENTAL
Intervention: 500 micrograms iodide/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100 micrograms levothyroxine and 100 micrograms iodide/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 micrograms iodide/day (initial treatment) followed by 100 micrograms levothyroxine and 100 micrograms iodide/day (combination treatment)
Number of subjects: 20
Study: 7011035

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (2 million IU of penicillin G intramuscularly before and after the procedure, followed by 350 mg of pivampicillin three times daily for 4 days)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 493
Study: 29779440

Group type: EXPERIMENTAL
Intervention: Positive inferential style training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative inferential style training
Number of subjects: 0
Study: 30177038

Group type: EXPERIMENTAL
Intervention: rhAPC (24 μg/kg/hr for ≤96 h antenatally)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rhAPC
Number of subjects: 9
Study: 26808546

Group type: EXPERIMENTAL
Intervention: Erlotinib in addition to gemcitabine
Number of subjects: 480

Group type: COMPARATOR
Intervention: Gemcitabine alone (placebo)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 480
Study: 24115735

Group type: EXPERIMENTAL
Intervention: Derivation cohort (n=504)
Number of subjects: 11288

Group type: EXPERIMENTAL
Intervention: Validation cohort (n=492)
Number of subjects: 11288

Group type: EXPERIMENTAL
Intervention: Risk algorithm model
Number of subjects: 11288

Group type: EXPERIMENTAL
Intervention: Mortality risk prediction
Number of subjects: 11288
Study: 23075043

Group type: EXPERIMENTAL
Intervention: Web-based social norms intervention with individualized social norms feedback after 5 months.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1000
Study: 20484334

Group type: EXPERIMENTAL
Intervention: Short breastfeeding duration (4 months)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Long breastfeeding duration (median 16 months)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Women with low baseline BMI
Number of subjects: 768
Study: 17397408

Group type: EXPERIMENTAL
Intervention: Methane producers
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-methane producers
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Methane production
Number of subjects: 87
Study: 16339586

Group type: EXPERIMENTAL
Intervention: recombinant modified vaccinia Ankara
Number of subjects: 0
Study: 12122904

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional neonatal intensive care
Number of subjects: 0
Study: 9874045

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 212

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 212